Medicus Pharma (MDCX) vs NeuroSense Therapeutics (NRSN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
NeuroSense Therapeutics is the larger company by market cap ($6.8 million vs $152,759), about 44.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDCX | NRSN |
|---|---|---|
| Share price | $0.1019 | $3.58 |
| Market cap | $152.76K | $6.79M |
| 1-day change | -36.39% | -6.28% |
| YTD return | -93.34% | — |
| 1-year return | -95.86% | — |
| EPS (TTM) | $-119.00 | $-47.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $139.00 | $26.64 |
| 52-week low | $0.0941 | $3.56 |
| Distance from 52-week high | -99.93% | -86.56% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +4316.09% | +2618.72% |
| Average volume | 92.96K | 21.29K |
| Shares outstanding | 1.50M | 1.90M |
| Employees | 16 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NeuroSense Therapeutics is about 44.5 times larger than Medicus Pharma by market value ($6.79M vs $152.76K).
About Medicus Pharma
MDCX stock →Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
About NeuroSense Therapeutics
NRSN stock →NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
MDCX vs NRSN FAQ
Which is bigger, Medicus Pharma or NeuroSense Therapeutics?
NeuroSense Therapeutics (NRSN) is larger, with a market capitalization of $6.79M compared with $152.76K for Medicus Pharma (MDCX).
Are Medicus Pharma and NeuroSense Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.